Transcatheter Mitral Valve Repair and
Replacement Market provides an in-depth analysis of the key winning strategies,
drivers & opportunities
The market for transcatheter mitral valve repair and replacement
is in the early stages. This is a new technology, because many healthcare
professionals and individuals do not know the benefits of surgery. The
transcatheter mitral valve repair and replacement market has emerged as an
effective treatment option for symptomatic severe mitral regurgitation (MR) in
patients who are considered untreatable or at high surgical risk for mitral
valve surgery.
Transcatheter Mitral Valve Repair
and Replacement Market is expected to reach at $1,878 million (both repair and replacement valves)
by 2023, registering a CAGR of 30.0% from 2017 to 2023. The mechanical valves
segment accounted for maximum share of the total market in 2016.
A mitral valve is a heart valve that allows blood to flow from
the heart chamber to the left atrium and to another valve called the left
ventricle. The mitral valve keeps blood flow in the proper direction and
prevents blood from flowing back. Valve repair and replacement is performed
when the left ventricle does not have enough blood, which can lead to bacterial
endocarditis, congestive heart failure, and even sudden death.
The report provides a comprehensive analysis of the key players
operating in the global transcatheter mitral valve repair & replacement
market such as
LivaNova Plc
Abbott Laboratories
Biotronik Pvt Ltd
Edward Lifesciences
Medtronic Plc
Neovasc Inc.
NeoChord
St. Jude Medical
Direct Flow Medical Inc.
Colibri Heart Valve LLC.
The other players in the value chain of the global transcatheter
mitral valve repair and replacement market include Venus Medtech, HLT Medical,
Transcatheter Technologies GmbH, MValve Technologies, Coramaze Technologies
GmbH, and Mardil Medical.
Increased elderly population and increased mitral valve
disorders are driving market growth. In addition, innovation and introduction
of new mitral valves are other factors that drive market growth. The main
constraints observed in this market are strict regulatory controls and the high
cost of mitral valve surgery and the high risks associated with these
procedures. In addition, the rise in health care costs and the emergence of
developing countries will provide opportunities for key market players.
The application of mitral stenosis is expected to maintain its
predominance during the forecast period due to the high prevalence of mitral
stenosis caused by rheumatic fever, an infectious heart disease. This has
created significant demand for transcatheter mitral valve repair and
replacement devices.
KEY FINDINGS OF THE STUDY
The U.S. was the major shareholder in
the North America transcatheter mitral
valve repair & replacement market, and accounted for the highest share in
2016.
Bioprosthetic tissue (biological) valves
is expected to grow at the significant CAGR of 30.5% during 2017-2023.
China occupied about
one-fourth share of the total Asia-Pacific transcatheter
mitral valve repair & replacement market in 2016. Whereas, India is expected to grow rapidly registering a
CAGR of 32.9% during the forecast period.
The mitral valve regurgitation segment is
growing at a highest CAGR of 33.5% from 2017 to 2023.
UK is anticipated to exhibit a highest
CAGR during the forecast period.
In 2016, Asia-Pacific and LAMEA
collectively accounted for about one-third share of the global transcatheter
mitral valve repair & replacement market and is expected to continue this
trend throughout the forecast period. Key factors driving the market include
the prevalence of mitral valve diseases and deaths caused owing to this
disease. Mitral valve diseases are sometimes inoperable and can be treated by
performing mitral valve surgeries.
No comments:
Post a Comment